Core Viewpoint - The arbitration case involving Jiangsu Jibeier Pharmaceutical Co., Ltd. and Shenzhen Huada Ocean Technology Co., Ltd. has reached a significant stage, with the Shanghai First Intermediate People's Court rejecting Huada Ocean's application to overturn the arbitration ruling [2][3][5] Group 1: Arbitration Case Overview - The arbitration was initiated by Jiangsu Jibeier Pharmaceutical against Huada Ocean regarding a share repurchase dispute related to Shenzhen Huahong Ocean Biological Pharmaceutical Co., Ltd. [2] - The Shanghai International Economic and Trade Arbitration Commission issued a ruling (No. 3816) on this matter, which is detailed in the company's announcements on the Shanghai Stock Exchange [2] Group 2: Recent Developments - Huada Ocean has filed an application to the Shanghai First Intermediate People's Court to annul the arbitration ruling, but the court has recently issued a civil ruling rejecting this application [2][3][5] - The ruling from the arbitration commission is considered final, and its impact on the company's financial performance will depend on the actual execution of the ruling [3][5]

Core Viewpoint - The stock of Jibeier has shown significant fluctuations, with a year-to-date increase of 52.10%, but recent declines in the short term indicate potential volatility in investor sentiment [1][2]. Group 1: Stock Performance - On October 15, Jibeier's stock rose by 2.02%, reaching a price of 33.28 CNY per share, with a trading volume of 18.48 million CNY and a turnover rate of 0.28% [1]. - The total market capitalization of Jibeier is 6.637 billion CNY [1]. - Year-to-date, the stock has increased by 52.10%, but it has decreased by 6.75% over the last five trading days and 8.42% over the last twenty days [1]. Group 2: Financial Performance - For the first half of 2025, Jibeier reported a revenue of 455 million CNY, representing a year-on-year growth of 4.90%, and a net profit attributable to shareholders of 149 million CNY, which is a 22.38% increase compared to the previous year [2]. - Since its A-share listing, Jibeier has distributed a total of 476 million CNY in dividends, with 296 million CNY distributed over the last three years [3]. Group 3: Business Overview - Jibeier, established on November 13, 2001, and listed on May 18, 2020, is primarily engaged in the research, production, and sales of pharmaceuticals [1]. - The main revenue sources for Jibeier include Likujun tablets (72.72%), Niqurolol tablets (14.20%), Yupingfeng capsules (4.88%), and other products [1]. - Jibeier operates within the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and formulations, and is involved in innovative drugs and cancer treatment [1].

案件所处的阶段：案件已裁决，深圳华大海洋科技有限公司（简称"华 大海洋"）向上海市第一中级人民法院申请撤销裁决 公司所处的当事人地位：仲裁阶段为申请人，上诉阶段为被申请人 上诉阶段裁定结果：驳回华大海洋的申请 对公司的影响：上海市第一中级人民法院作出裁定，驳回华大海洋的申 请。《裁决书》（上国仲（2024）第 3816 号）为终局裁决，对公司当期 及期后损益等影响最终以实际执行情况为准。 二、本次仲裁事项的进展情况 江苏吉贝尔药业股份有限公司 关于仲裁事项进展的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次仲裁事项的基本情况 江苏吉贝尔药业股份有限公司（简称"公司"）与华大海洋（为标的公司控 股股东，仲裁阶段为被申请人，上诉阶段为申请人）因深圳华泓海洋生物医药有 限公司（为标的公司）股权回购产生纠纷，公司向上海国际经济贸易仲裁委员会 （上海国际仲裁中心）提起仲裁，上海国际经济贸易仲裁委员会（上海国际仲裁 中心）作出《裁决书》（上国仲（2024）第 3816 号），具体内容详见公司披露于 上海证 ...

Group 1 - The core point of the news is that Jibeier's stock price has dropped by 5.07%, currently trading at 32.77 CNY per share, with a total market capitalization of 6.535 billion CNY [1] - Jibeier Pharmaceutical Co., Ltd. is located in Zhenjiang, Jiangsu Province, established on November 13, 2001, and listed on May 18, 2020. The company specializes in drug research, production, and sales [1] - The main revenue composition of Jibeier includes: Likujun tablets (72.72%), Niqunlol tablets (14.20%), Yupingfeng capsules (4.88%), others (4.53%), and Acetylsalicylic acid enteric-coated tablets (3.67%) [1] Group 2 - From the perspective of major fund holdings, one fund under GF Fund has a significant position in Jibeier. The fund, GF Stable Growth Mixed A (002622), held 10,500 shares in the second quarter, accounting for 0.51% of the fund's net value, ranking as the third-largest holding [2] - The current scale of GF Stable Growth Mixed A is 55.5805 million CNY, with a year-to-date return of 4.44%, ranking 6997 out of 8234 in its category [2] - The fund manager of GF Stable Growth Mixed A is Qiu Shilei, who has been in the position for 9 years and 261 days, with the best fund return during his tenure being 64.45% [3]

Core Viewpoint - The stock of Jibeier has experienced fluctuations, with a year-to-date increase of 59.41% but a recent decline in the last five and twenty trading days [1] Group 1: Stock Performance - As of October 10, Jibeier's stock price was 34.88 CNY per share, with a market capitalization of 6.956 billion CNY [1] - The stock has seen a recent decline of 2.02% in intraday trading, with a trading volume of 37.4161 million CNY and a turnover rate of 0.53% [1] - Year-to-date, the stock has increased by 59.41%, but it has decreased by 2.43% over the last five trading days and 10.01% over the last twenty trading days [1] Group 2: Financial Performance - For the first half of 2025, Jibeier reported a revenue of 455 million CNY, representing a year-on-year growth of 4.90% [2] - The net profit attributable to shareholders for the same period was 149 million CNY, showing a year-on-year increase of 22.38% [2] Group 3: Shareholder Information - As of June 30, the number of Jibeier shareholders was 6,003, a decrease of 17.68% from the previous period [2] - The average number of circulating shares per shareholder increased by 21.47% to 33,221 shares [2] Group 4: Dividend Information - Jibeier has distributed a total of 476 million CNY in dividends since its A-share listing, with 296 million CNY distributed over the past three years [3]

证券代码：688566 证券简称：吉贝尔 公告编号：2025-044 江苏吉贝尔药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （一）会议线上交流时间：2025 年 10 月 17 日（星期五）下午 15:00-16:00 1 重要内容提示： 会议线上交流时间：2025 年 10 月 17 日（星期五）下午 15:00-16:00 会议召开方式：线上文字互动 线 上 文 字 互 动 平 台 ： 东 方 财 富 路 演 平 台 （ 网 址 ： http://roadshow.eastmoney.com/luyan/4912335） 投资者可于 2025 年 10 月 16 日（星期四）16:00 前通过邮件、电话等形式 将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普 遍关注的问题进行回答。 江苏吉贝尔药业股份有限公司（以下简称"公司"）已于 2025 年 8 月 30 日在上海证券交易所网站（www.sse.com.cn）发布《公司 2025 ...

Group 1 - The core point of the announcement is the resolution of the second extraordinary general meeting of shareholders held by Jiangsu Jibeier Pharmaceutical Co., Ltd. on September 26, 2025, which included the approval of a significant amendment to the company's governance structure [1][2]. - The meeting was conducted in compliance with the Company Law and the company's articles of association, with a combination of in-person and online attendance [2][4]. - All current directors and supervisors attended the meeting, ensuring full representation of the board [3]. Group 2 - A key resolution passed during the meeting was the proposal to abolish the supervisory board and amend the company's articles of association and certain governance systems, which received more than two-thirds of the valid votes from attending shareholders [4]. - The legal proceedings of the meeting were witnessed by Beijing Jindu (Nanjing) Law Firm, confirming that all procedures adhered to legal and regulatory requirements [6].

重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 证券代码：688566 证券简称：吉贝尔 公告编号：2025-043 江苏吉贝尔药业股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 1、出席会议的股东和代理人人数 | 50 | | --- | --- | | 普通股股东人数 | 50 | | 2、出席会议的股东所持有的表决权数量 | 134,820,879 | | 普通股股东所持有表决权数量 | 134,820,879 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 67.6028 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 67.6028 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次会议由公司董事会召集，由董事长耿仲毅先生主持，会议采用现场结合 1 （ ...

北京市金杜（南京）律师事务所（以下简称本所）接受江苏吉贝尔药业股 份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》《中华人 民共和国公司法》、中国证券监督管理委员会（以下简称中国证监会）《上市 公司股东会规则（2025 修订）》（以下简称《股东会规则》）等中华人民共和 国境内（以下简称中国境内，为本法律意见书之目的，不包括中华人民共和国 香港特别行政区、中华人民共和国澳门特别行政区和中华人民共和国台湾省） 现行有效的法律、行政法规、规章及规范性文件和现行有效的公司章程有关规 定，指派律师出席了公司于 2025 年 9 月 26 日召开的 2025 年第二次临时股东 大会（以下简称本次股东大会），并就本次股东大会相关事项出具本法律意见 书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限 于： 1 1. 经公司 2021 年第一次临时股东大会授权、第四届董事会第十一次会议 审议通过的《江苏吉贝尔药业股份有限公司章程》（以下简称《公司章 程》）； 2. 公司于 2025 年 8 月 29 日召开的第四届董事会第十七次会议及第四届 监事会第十六次会议的议案、决议等文件； 3. 公 司 ...

Group 1 - The stock price of Jibeier has dropped by 5.08% on September 23, reaching 34.20 CNY per share, with a trading volume of 81.19 million CNY and a turnover rate of 1.16%, resulting in a total market capitalization of 6.821 billion CNY. The stock has experienced a continuous decline for six days, with a cumulative drop of 6.29% during this period [1] - Jibeier Pharmaceutical Co., Ltd. is located in the High-tech Industrial Development Zone of Zhenjiang, Jiangsu Province, established on November 13, 2001, and listed on May 18, 2020. The company's main business involves drug research and development, production, and sales. The revenue composition is as follows: Likujun tablets 72.72%, Nigulol tablets 14.20%, Yipingfeng capsules 4.88%, others 4.53%, and Acetylsalicylic acid enteric-coated tablets 3.67% [1] Group 2 - According to data from the top ten heavy stocks of funds, one fund under GF Fund holds Jibeier as a significant investment. The GF Stable Growth Mixed A Fund (002622) held 10,500 shares in the second quarter, accounting for 0.51% of the fund's net value, making it the third-largest heavy stock. The estimated floating loss today is approximately 19,300 CNY, with a total floating loss of 25,500 CNY during the six-day decline [2] - The GF Stable Growth Mixed A Fund (002622) was established on June 27, 2016, with a latest scale of 55.5805 million CNY. Year-to-date return is 4.32%, ranking 6825 out of 8172 in its category; the one-year return is 6.46%, ranking 7353 out of 7995; and the return since inception is 36.36% [2]